PETER WIRTH
CIK 1021041 · Exec VP,Legal & Corporate Dev. · last filed 2025-06-23
PETER WIRTH is an Exec VP,Legal & Corporate Dev. who has filed 33 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for ZLAB, was dated Jun 23, 2025. Across all open-market trades the lifetime net is −$17.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.79M
5
33
-$17.89M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZLAB | Director | 397,750 | $17.07 | $6.79M | $293.3K | 8 | 2025-06-23 |
| SYRS | Director | 16,000 | $0.00 | $6 | $0 | 9 | 2024-06-07 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 5 | 2022-10-14 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | — | — | — | $0 | 3 | 2015-06-23 |
| GENZYME CORP (GENZ) Delisted | Exec VP,Legal & Corporate Dev. | 0 | — | — | -$18.18M | 8 | 2011-04-06 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-23 | ZLAB | Grant (A) | +10,831 | $0 | EDGAR |
| 2024-06-20 | ZLAB | Grant (A) | +21,253 | $0 | EDGAR |
| 2024-06-07 | SYRS | Grant (A) | +4,000 | $0 | EDGAR |
| 2023-06-30 | ZLAB | Grant (A) | +18,903 | $500.0K | EDGAR |
| 2023-06-02 | SYRS | Grant (A) | +4,000 | $0 | EDGAR |
| 2022-12-12 | ZLAB | Buy (P) | +4,000 | $285.4K | EDGAR |
| 2022-12-09 | ZLAB | Sell (S) | −7,852 | -$277.6K | EDGAR |
| 2022-10-14 | Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Mixed | −134,915 | $0 | EDGAR |
| 2022-09-19 | SYRS | Grant (A) | +8,000 | $0 | EDGAR |
| 2022-06-09 | Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Grant (A) | +4,500 | $0 | EDGAR |